In 2024, Wegovy was also approved to help lower the risk of death due to heart disease, heart attack, and stroke in adults with known heart conditions who also have excess weight or obesity.

A new study found semaglutide, sold as the popular diabetes and weight loss drugs Ozempic and Wegovy, was not linked to an increased risk of suicidal ideation compared with other weight loss drugs.

The obesity drug Wegovy can reduce the risk of severe heart problems by 20%, a pivotal study finds, paving the way for applications far beyond weight loss. AP/ Novo Nordisk. 3.

Folks who take Ozempic or Wegovy for diabetes and weight loss need not worry about a higher risk of suicidal thoughts or feelings while on the medications, a new, large review finds. In the study ...

The results of a new clinical trial show that Wegovy is linked to a reduced risk of heart attack, stroke, and heart-related death. Ozempic, a drug similar to Wegovy, had a similar clinical ...

Wegovy successfully decreased the risk of major adverse cardiovascular events by 20% in patients over a five-year period, the drug's manufacturer Novo Nordisk announced on Tuesday.

The weight loss drug Wegovy was shown to reduce the risk of heart attack, stroke or heart-related death by 20% in a clinical trial in people with cardiovascular disease. Skip to content.

The weight loss drug Wegovy was shown to reduce the risk of heart attack, stroke or heart-related death by 20% in a clinical trial in people with cardiovascular disease. Skip to content.

The weight loss drug Wegovy was shown to reduce the risk of heart attack, stroke or heart-related death by 20% in a clinical trial in people with cardiovascular disease. Skip to content.

The weight loss drug Wegovy was shown to reduce the risk of heart attack, stroke or heart-related death by 20% in a clinical trial in people with cardiovascular disease. Skip to content.

The weight loss drug Wegovy was shown to reduce the risk of heart attack, stroke or heart-related death by 20% in a clinical trial in people with cardiovascular disease. Skip to content.

The weight loss drug Wegovy was shown to reduce the risk of heart attack, stroke or heart-related death by 20% in a clinical trial in people with cardiovascular disease. Skip to content.